Tanja Obradovic on Radiopharmaceuticals in oncology
Tanja Obradovic shared a post on LinkedIn:
“Radiopharmaceuticals in oncology have been recently very active clinical development target as well as business focus area. Currently approved radiotherapeutics are Pluvicto for metastatic prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) and Lutathera for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, both by Novartis. Novartis radiopharmaceutical pipeline is likely to get stronger since in April Novartis announced expansion of work with PeptiDream on peptide-based radioligand therapies and then at the beginning of this month buyout of radiopharmaceutical company Mariana Oncology.
This activity follows previous deals of Big Pharma focusing on radiotherapies where Bristol Myers Squibb purchased RayzeBio at the end of 2023 and AstraZeneca picked up Fusion Pharmaceuticals in March 2024.
Latest addition is just announced -collaboration between Eli Lilly and Aktis Oncology and it comes on top of previous Lilly acquisition of Point Biopharma in October 2023.
All this indicates many more radiotherapeutics coming to clinical evaluation as potential cancer therapies.”